Investors Purchase Large Volume of Put Options on Recursion Pharmaceuticals (NASDAQ:RXRX)

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) saw unusually large options trading activity on Tuesday. Investors purchased 20,530 put options on the stock. This represents an increase of 32% compared to the typical volume of 15,579 put options.

Insider Buying and Selling at Recursion Pharmaceuticals

In other news, CEO Najat Khan sold 23,588 shares of the stock in a transaction on Friday, June 5th. The stock was sold at an average price of $3.58, for a total value of $84,445.04. Following the completion of the transaction, the chief executive officer directly owned 2,175,796 shares in the company, valued at approximately $7,789,349.68. This represents a 1.07% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Blake Borgeson sold 40,000 shares of the firm’s stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $3.96, for a total value of $158,400.00. Following the sale, the director directly owned 6,218,287 shares in the company, valued at approximately $24,624,416.52. This trade represents a 0.64% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 131,937 shares of company stock valued at $478,874 over the last quarter. Company insiders own 6.65% of the company’s stock.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. boosted its stake in Recursion Pharmaceuticals by 18.6% during the fourth quarter. Vanguard Group Inc. now owns 47,187,759 shares of the company’s stock valued at $192,998,000 after buying an additional 7,407,606 shares during the period. State Street Corp increased its stake in Recursion Pharmaceuticals by 38.7% in the 4th quarter. State Street Corp now owns 25,333,888 shares of the company’s stock worth $103,616,000 after acquiring an additional 7,064,963 shares during the last quarter. Norges Bank bought a new position in Recursion Pharmaceuticals in the 4th quarter worth about $23,473,000. ARK Investment Management LLC raised its holdings in shares of Recursion Pharmaceuticals by 11.2% in the 4th quarter. ARK Investment Management LLC now owns 37,316,856 shares of the company’s stock valued at $152,626,000 after acquiring an additional 3,771,357 shares in the last quarter. Finally, Renaissance Technologies LLC purchased a new stake in shares of Recursion Pharmaceuticals in the 1st quarter valued at about $7,370,000. 89.06% of the stock is owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Stock Performance

NASDAQ RXRX opened at $3.35 on Wednesday. Recursion Pharmaceuticals has a 52-week low of $2.77 and a 52-week high of $7.18. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.03 and a current ratio of 5.03. The company has a 50-day simple moving average of $3.30 and a 200 day simple moving average of $3.43. The company has a market capitalization of $1.78 billion, a PE ratio of -3.22 and a beta of 1.03.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.01). The business had revenue of $7.67 million during the quarter, compared to the consensus estimate of $10.97 million. Recursion Pharmaceuticals had a negative return on equity of 50.41% and a negative net margin of 945.94%.During the same period last year, the business posted ($0.41) earnings per share. On average, research analysts predict that Recursion Pharmaceuticals will post -0.89 EPS for the current year.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. JPMorgan Chase & Co. dropped their price objective on shares of Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating for the company in a report on Thursday, April 30th. Wall Street Zen lowered shares of Recursion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday. Morgan Stanley upped their price target on shares of Recursion Pharmaceuticals from $5.00 to $5.50 and gave the company an “equal weight” rating in a research report on Thursday, May 14th. Needham & Company LLC reaffirmed a “buy” rating and set a $8.00 price target on shares of Recursion Pharmaceuticals in a research note on Thursday, May 7th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Friday, July 17th. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Recursion Pharmaceuticals currently has an average rating of “Hold” and an average target price of $8.10.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.